13122-67-3

Basic information

• Product Name: 6-phenyl-4-oxohexanoic acid
• Synonyms: 6-phenyl-4-oxohexanoic acid
• CAS NO: 13122-67-3
• Molecular Weight: 206.241
• Mol File: 13122-67-3.mol
• Article Data: 6

Chemical Properties

• CAS DataBase Reference: 6-phenyl-4-oxohexanoic acid(CAS DataBase Reference)
• NIST Chemistry Reference: 6-phenyl-4-oxohexanoic acid(13122-67-3)
• EPA Substance Registry System: 6-phenyl-4-oxohexanoic acid(13122-67-3)

Safety Data

• Hazardous Substances Data: 13122-67-3(Hazardous Substances Data)

Upstream product

• 90147-73-2 ethyl 4-oxo-6-phenylhexanoate 
• 121748-58-1 ethyl (trans)-6-phenyl-4-oxo-5-hexenoate 
• 100-52-7 benzaldehyde 
• 108-30-5 succinic acid anhydride 
• 3277-89-2 phenethylmagnesium bromide 
• 64-17-5 ethanol 
• 121365-22-8 (E)-4-oxo-6-phenylhex-5-enoic acid 
• 645-45-4 hydrocinnamic acid chloride 
• 170943-52-9 diethyl (E)-2-(2-phenylethyl)-3,4-dehydroglutamate 
• 66487-97-6 1-(furan-2-yl)-2-phenylethanol 
• 123-76-2 levulinic acid 

Downstream Products

• 90147-73-2 ethyl 4-oxo-6-phenylhexanoate 
• 112607-22-4 (+)-(R)-5-(2-phenylethyl)dihydrofuran-2(3H)-one 
• 112606-95-8 5-(1-phenylethyl)-2-tetrahydrofuranone 
• 138298-28-9 Acetic acid (R)-4-hydroxy-6-phenyl-hexyl ester 
• 138298-28-9 Acetic acid (S)-4-hydroxy-6-phenyl-hexyl ester 
• 138298-29-0 Acetic acid (S)-1-phenethyl-butyl ester 
• 138298-29-0 Acetic acid (R)-1-phenethyl-butyl ester 
• 2430-76-4 (R)-6-Phenyl-hexane-1,4-diol 
• 138298-27-8 (S)-6-Phenyl-hexane-1,4-diol 
• 138381-24-5 (S,E)-5-styryldihydrofuran-2(3H)-one 
• 114361-75-0 (R,E)-5-styryldihydrofuran-2(3H)-one 
• 134627-14-8 (+)-1-Phenyl-hexan-3-ol 

Relevant articles and documents

Acyl acid derivative and preparation method and medical application thereof

The invention relates to an acyl acid derivative as well as a preparation method and medical application thereof. Specifically, the invention relates to a compound represented by a general formula (I), a pharmaceutically acceptable salt thereof, or a pharmaceutical composition containing the same, and the invention also relates to a use thereof as an active ingredient in the prevention and/or treatment of muscle atrophy-related diseases, including myogenic muscle atrophy, disuse muscle atrophy, senile muscle atrophy, neurogenic muscle atrophy, and a use in the prevention and/or treatment of obesity, fatty liver, cardiovascular and cerebrovascular diseases, metabolic diseases, and anti-aging, wherein the definition of each group in the general formula (I) is the same as the definition in the specification.

Preparation and Application of Amino Phosphine Ligands Bearing Spiro[indane-1,2′-pyrrolidine] Backbone

P,Nsp3-bidentate chiral ligands bearing spiro[indane-1,2′-pyrrolidine] backbone were prepared in gram scale for the first time. Pd complexes of these air-stable amino phosphine ligands could catalyze asymmetric allylic substitutions of malonate-, alcohol-, and amine-type nucleophiles in up to 97percent ee and 99percent yield. A crystal structure of [Pd(II)(η3-1,3-diphenylallyl)(ligand)]PF6 indicated possible transition states of the catalytic reactions. These ligands are characteristic of a very rigid backbone, which is simple but highly effective. They rival C2-symmetric bisphosphine, P,Nsp2-bidentate, and P,Nsp3-bidentate ligands in tested allylic substitutions. ?

Asymmetric synthesis of spiro 2-pyrrolidin-5-ones, 2-piperidin-6-ones and 1-isoindolin-3-ones. Part 1: N-acyliminium ion cyclisations with an internal arene nucleophile

A series of chiral non-racemic 5,5- and 5,6-bicyclic lactams is prepared from (R)-phenylglycinol. These are isomerised on treatment with aluminium trichloride in 1,2-dichloroethane to give spiro lactams in high yield and >3:1 diastereoselectivity. From four structures determined by X-ray crystallography, it follows that spiro indenes are formed preferentially with retention of configuration at the spiro carbon atom and spiro naphthalenes with inversion.